


Global pipeline of products for neglected diseases



80% OF ALL CANDIDATES IN THE PIPELINE HAVE A PUBLIC SECTOR PARTNER

Ongoing need

Lack of essential health technologies

- No HIV/AIDS vaccine
- TB treatment lasts 6–30 months, TB vaccine almost 100 years old
- No suitable treatments for Chagas, leishmaniasis, or sleeping sickness
- New disease threats continue to emerge



1 billion
PEOPLE AFFECTED BY
NEGLECTED DISEASES GLOBALLY


214 million

WOMEN HAVE UNMET NEED
FOR MODERN FAMILY PLANNING


6 million

ANNUAL DEATHS WORLDWIDE
FROM NEGLECTED DISEASES

Funding for neglected disease R&D



The return on investment of global health R&D



Critical US role in global health R&D


51%
of new global health products approved since 2000 were supported by the US government

40%
of late-stage products in the global health pipeline were supported by the US government

<.01%
of US GDP is spent annually on global health R&D

Top public funders of neglected disease R&D

(Investment as a percent of GDP)



While the US leads the world in funding for neglected disease R&D, these investments still account for less than .01% of US GDP



Infographic Data Sources

Global pipeline for neglected diseases

All data: Chapman N. The unrecognised revolution in global health. Sydney: Policy Cures; 2015.

Funding for neglected disease R&D

\$274 billion global spending on all health R&D: Røttingen, J-E, Regmi, S, Eide, M et al. Mapping of available health research and development data: what's there, what's missing and what role is there for a global observatory. *Lancet*. 2013; 383:1286–1307. [Data is for total global spending on health R&D in 2009 purchasing power parity-adjusted dollars, the most recent year available.]

\$3.2 billion global spending on neglected disease R&D/Neglected disease R&D by sector: Chapman N, Doubell A, et al. Neglected Disease Research and Development: Reflecting on a Decade of Global Investment. *G-FINDER* | 2017. Sydney: Policy Cures Research; 2017.

Return on investment in global health R&D

New health innovations resulted in 4.2 million fewer child deaths: Wang H, Liddell CA, Coates MM, et al. Global, regional, and national levels of neonatal, infant, and under-5 mortality during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. *The Lancet*. 2014.

Antiretroviral therapies prevented 78 million deaths: UNAIDS. AIDS by the numbers 2015. Geneva: UNAIDS; 2015.

\$.89 of every US dollar: Policy Cures Research, Global Health Technologies Coalition. Return on innovation: Why global health R&D is a smart investment for the United States. Sydney: Policy Cures Research; 2017.

€.80 of every euro: Policy Cures, Deutsche Stiftung Weltbevölkerung. Saving lives: Making the case for European investment in poverty-related and neglected disease R&D. Sydney: Policy Cures; 2016.

11% of economic growth in low-and middle-income countries: Jamison DT, Summers LH, Alleyne G, et al. Global health 2035: a world converging within a generation. *The Lancet*. 2013;382(9908):1859–1861.

US government investment in global health R&D from 2007–2015: Policy Cures Research, Global Health Technologies Coalition. Return on innovation: Why global health R&D is a smart investment for the United States. Sydney: Policy Cures Research; 2017.

\$26 million invested in polio vaccine R&D: Thompson KM, Tebbens RJ Retrospective cost-effectiveness analyses for polio vaccination in the United States. *Risk Anal*. 2006; 26(6):1423–40.

Every \$1 invested in HIV vaccine R&D: Hecht R, Jamison DT. Vaccine research and development assessment paper In: Lomborg B, ed. Rethink HIV: smarter ways to invest in ending HIV in sub-Saharan Africa. New York: Cambridge University Press, 2012; 299–320.

Meningitis A vaccine predicted to have saved \$9 billion: Stack M, Ozawa, S, Bishai, D, et al. Estimated Economic Benefits During The 'Decade Of Vaccines' Include Treatment Savings, Gains in Labor Productivity. *Health Affairs*. 2011.

The 2014 Ebola epidemic cost the US \$3 billion: Cost of the Ebola Epidemic [Ebola Hemorrhagic Fever | US Centers for Disease Control and Prevention [Internet]. [cited 2017 Mar 22]. Available from: <https://www.cdc.gov/vhf/ebola/outbreaks/2014-west-africa/cost-of-ebola.html>

The 2014 Ebola epidemic cost the EU \$1.2 billion: EU response to the Ebola outbreak | European Commission [Internet]. [cited 2017 July 9]. Available from: https://ec.europa.eu/europeaid/regions/africa/west-africa/ebola-response_en

Pandemics could cost the world \$60 billion a year: Commission on a Global Health Risk Framework for the Future. The neglected dimension of global security: A framework to counter infectious disease crises. National Academy of Sciences. 2016.

Ongoing need

1 billion people affected by neglected diseases: World Health Organization (WHO). Investing to Overcome the Global Impact of Neglected Tropical Diseases: Third WHO Report on Neglected Tropical Diseases. Geneva: WHO; 2015.

6 million annual deaths from neglected diseases: Institute for Health Metrics and Evaluation (IHME). Global Burden of Disease Study 2010 (GBD 2010) Results by Cause and by Region 1990-2010. 2013.

214 million women have unmet family planning needs: Adding it Up: Investing in Contraception and Maternal and Newborn Health, 2017. New York: Guttmacher Institute, 2017.

Critical US role in global health R&D

All data: Policy Cures Research, Global Health Technologies Coalition. Return on innovation: Why global health R&D is a smart investment for the United States. Sydney: Policy Cures Research; 2017.

Top public funders of neglected disease R&D

All data: Chapman N, Doubell A, et al. Neglected Disease Research and Development: Reflecting on a Decade of Global Investment. *G-FINDER* | 2017. Sydney: Policy Cures Research; 2017.